Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Comparison Of All FK-506 Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Renal transplant recipients, males or females, of 18 years of age or above.~2. Able to participate and willing to give written informed consent and to comply with study visits and restrictions.~3. Able to understand English.~4. Patients having received a primary or secondary renal transplant~Exclusion Criteria:~1. Evidence of acute rejection episode within the past three months prior to screening.~2. Recipients of organ transplants other than kidney.~3. Patients who are known to be HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prograf vs Envarsus XR vs Astagraf XL (Type: ACTIVE_COMPARATOR): Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
- Prograf vs Astagraf XL vs Envarsus XR (Type: ACTIVE_COMPARATOR): Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).